INmune Bio (NASDAQ:INMB) Stock Price Down 0.2%

INmune Bio, Inc. (NASDAQ:INMB)’s stock price traded down 0.2% on Tuesday . The stock traded as low as $10.94 and last traded at $11.18. 63,843 shares changed hands during trading, a decline of 39% from the average session volume of 104,750 shares. The stock had previously closed at $11.20.

INmune Bio Trading Down 0.2 %

The company’s 50-day moving average price is $11.14 and its two-hundred day moving average price is $10.65. The company has a market cap of $203.48 million, a P/E ratio of -6.69 and a beta of 1.92.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, March 28th. The company reported ($0.47) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter. INmune Bio had a negative return on equity of 64.11% and a negative net margin of 19,360.00%.

Institutional Trading of INmune Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Janney Montgomery Scott LLC lifted its holdings in shares of INmune Bio by 14.5% in the third quarter. Janney Montgomery Scott LLC now owns 256,887 shares of the company’s stock valued at $1,739,000 after purchasing an additional 32,482 shares in the last quarter. Fermata Advisors LLC purchased a new stake in INmune Bio in the 3rd quarter worth about $384,000. Bank of New York Mellon Corp purchased a new stake in INmune Bio in the 3rd quarter worth about $223,000. Finally, Financial Advocates Investment Management boosted its position in INmune Bio by 8.6% during the 4th quarter. Financial Advocates Investment Management now owns 12,500 shares of the company’s stock worth $141,000 after acquiring an additional 990 shares during the period. Institutional investors and hedge funds own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.